Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05889988 · ClinicalTrials.gov registry record
A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients
A clinical trial of Breast Neoplasm, sponsored by Mayo Clinic.
- Active
- Registry status
- 36
- Enrollment target
- 20
- Study locations
NCT05889988: Active study of Breast Neoplasm, sponsored by Mayo Clinic.
NCT05889988 is a study of Breast Neoplasm that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 36 participants, below the 161-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05889988, a study of Breast Neoplasm, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 36 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers plan to study the natural history of ado-trastuzumab emtansine (T-DM1)-induced neuropathy both in patients without any history of neuropathy or previous neurotoxic agent use and in patients who have such a history.
Primary Outcome
Measured using the European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-induced peripheral neuropathy (CIPN) twenty-item scale (EORTC QLQCIPN20), a validated instrument designed to elicit cancer patients' experience of symptoms and functional limitations related to chemotherapy-induced peripheral neuropathy. The total score of CIPN20, each of the three subscale scores (sensory, motor, autonomic), and each individual item of the CIPN20 tool will be
Conditions Studied
Study Locations (20)
Minnesota
- Riverwood Healthcare Center - Aitkin
- Essentia Health Baxter Clinic - Baxter
- Essentia Health Saint Joseph's Medical Center - Brainerd
- Essentia Health - Deer River Clinic - Deer River
- Essentia Health Saint Mary's - Detroit Lakes Clinic - Detroit Lakes
- Essentia Health Cancer Center - Duluth
- Essentia Health Ely Clinic - Ely
- Essentia Health - Fosston - Fosston
- Fairview Grand Itasca Clinic & Hospital - Grand Rapids
- Essentia Health Hibbing Clinic - Hibbing
- Fairview Range Medical Center - Hibbing
- Essentia Health - International Falls Clinic - International Falls
- MMCORC CentraCare Monticello Cancer Center - Monticello
- Essentia Health Moose Lake - Moose Lake
- Essentia Health - Park Rapids - Park Rapids
- Fairview Northland Medical Center - Princeton
- Mayo Clinic in Rochester - Rochester
- Essentia Health Sandstone - Sandstone
- Sanford Health Thief River Falls Clinic - Thief River Falls
- Essentia Health Virginia Clinic - Virginia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-06-12 |
| Est. Completion | 2027-08 |
What the registry record for NCT05889988 still lists
NCT05889988 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 161-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Breast Neoplasm appearing as the primary indexed condition, and to 0 interventions.
NCT05889988 names 20 study sites across 1 states, led by Minnesota.
Frequently Asked Questions
What is clinical trial NCT05889988 about?
NCT05889988 is a clinical study titled "A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients". Researchers plan to study the natural history of ado-trastuzumab emtansine (T-DM1)-induced neuropathy both in patients without any history of neuropathy or previous neurotoxic agent use and in patients who have such a history.
What is the current status of trial NCT05889988?
This trial is currently active not recruiting. The enrollment target is 36 participants. The study started on 2023-06-12. Estimated completion is 2027-08.
What conditions does trial NCT05889988 study?
This clinical trial studies the following conditions: Breast Neoplasm.
Who is sponsoring clinical trial NCT05889988?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05889988 being conducted?
This trial has 20 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05889988's enrollment target sits among peer trials
36 22nd of 26 higher than 5 of 26 other Breast Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Surviving Daily Life
RECRUITING
-
Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities
RECRUITING · NA
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Cryoablation vs Lumpectomy in T1 Breast Cancers
RECRUITING · NA
-
Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
RECRUITING · NA
-
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI